

MEDICAL LABORATORY EVALUATION

PARTICIPANT SUMMARY

2 • 0 • 0 • 8

Please see the corresponding US participant summary for any statistics not represented in this supplement.



Total Commitment to Education and Service
Provided by ACP Services, Inc.

**International Data Supplement
MLE – M1**

Table of Contents

2008 Evaluation Criteria	3
---------------------------------------	----------

Coagulation

Prothrombin Time	4
International Normalized Ratio (INR)	6
Activated Partial Thromboplastin Time	8
Fibrinogen	9

Urinalysis

Urinalysis Dipstick	10
Specific Gravity	10
pH	11
Protein	11
Glucose or Reducing Substance	12
Ketones.....	12
Bilirubin	13
Urobilinogen.....	13
Blood or Hemoglobin	14
Leukocyte Esterase	14
Nitrite	15
Microalbumin (Dipstick Only)	15
Urine hcG	15

Microbiology

Antimicrobial Susceptibility Testing	16
Parasitology (PA Specimens)	17
Parasitology (FP Specimens)	18

Immunology

Syphilis Serology	20
VDRL Slide	20
VDRL Slide (Titer).....	20
MHA-TP	21
FTA-ABS.....	21
RPR	22
RPR (Titer).....	23

Viral Markers	24
Anti-HBc.....	24
Anti-HIV	25
HAV	26
HBeAg	27
HBsAb.....	28
HBsAg.....	29
HCV	30

Chemistry

Blood Gases	31
--------------------------	-----------

2008 Evaluation Criteria

The evaluation criteria used in the 2008 MLE Program is in accordance with the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88) federal requirements for proficiency testing. The criteria are included below.

Qualitative

For qualitative procedures, evaluation is based on participant consensus. A minimum percentage of participants must receive a passing score or the challenge is not evaluated due to lack of consensus. These percentages are listed below.

Antimicrobial Susceptibility Testing	80% Consensus
Microalbumin (Semi-Quantitative)	80% Consensus
Parasite Identification	80% Consensus
Syphilis Serology	80% Consensus
Urine Dipstick	80% Consensus
Urine hCG	80% Consensus
Viral Markers	80% Consensus

Quantitative

For quantitative procedures, a mean and standard deviation (SD) are calculated for each peer group consisting of 5 or more laboratories. Acceptable performance is established based on a target value \pm the intervals below. An explanation on how to calculate the range of acceptability based upon these limits is also provided in your MLE Program Guide on pages 39-40 under the heading "Acceptable Ranges for Quantitative Results."

Activated Partial Thromboplastin Time	\pm 15 percent
Calcium, Ionized	\pm 3 SD
Chloride	\pm 5%
Fibrinogen	\pm 20 percent
International Normalized Ratio	\pm 3 SD
pCO ₂	\pm 5 mmHg or 8% *
pH	\pm 0.04
pO ₂	\pm 3 SD
Potassium	\pm 0.5 mmol/L
Prothrombin Time	\pm 15 percent
Sodium	\pm 4.0 mmol/L
Specific Gravity	\pm 0.010

*Whichever is greater

PROTHROMBIN TIME (seconds)**Specimen CG-5**

<u>Reagent/Instruments</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	145	31.70	5.41	17.1	32.0
bioMerieux Simplastin Excel S					
bioMerieux Thrombotimer	6	37.03	2.47	6.7	38.0
All Coagulation Instruments	19	37.62	3.08	8.2	36.9
Dade Innovin					
Sysmex CA-1000/1500	6	24.70	0.93	3.7	24.8
Sysmex CA-500	5	24.28	1.47	6.0	25.1
All Coagulation Instruments	13	24.52	1.06	4.3	24.8
Dade Thromborel S					
Sysmex CA-1000/1500	5	35.08	3.30	9.4	35.1
Sysmex CA-500	7	33.36	1.86	5.6	32.9
All Coagulation Instruments	21	34.55	2.66	7.7	34.8
Diag Stago STA Neoplastine Cl+					
RAL Clot-SP	11	35.58	1.35	3.8	35.7
HUMAN HemoStat Thromboplastin - SI					
All Coagulation Instruments	14	37.98	5.47	14.4	38.2
IL TEST PT-FIB Recombinant					
IL ACL, all models	39	28.45	2.19	7.7	28.3
TEClot PT					
Coatron M2 / M4	6	32.30	3.13	9.7	33.5
Wiener Lab Soluplastin					
All Coagulation Instruments	5	31.76	2.57	8.1	31.9

PROTHROMBIN TIME-INTERNATIONAL NORMALIZED RATIO (INR)

<u>Reagent/Instruments</u>	Specimen CG-1					Specimen CG-2				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	150	4.42	0.81	18.4	4.3	153	0.96	0.10	10.5	1.0
bioMerieux Simplastin Excel S										
bioMerieux Thrombotimer	8	4.29	0.47	11.0	4.4	8	0.99	0.06	6.5	1.0
All Coagulation Instruments	21	4.41	0.87	19.8	4.2	22	0.99	0.06	6.5	1.0
Dade Innovin										
Sysmex CA-1000/1500	5	3.66	0.36	10.0	3.7	6	0.95	0.05	5.8	1.0
Sysmex CA-500	5	3.88	0.43	11.1	3.9	5	0.92	0.04	4.9	0.9
All Coagulation Instruments	12	3.73	0.41	11.1	3.9	13	0.94	0.05	5.4	0.9
Dade Thromborel S										
Sysmex CA-1000/1500	5	4.40	0.53	12.0	4.5	5	1.00	0.10	10.0	1.0
Sysmex CA-500	8	4.36	0.36	8.2	4.5	8	0.91	0.22	23.7	0.9
All Coagulation Instruments	22	4.47	0.38	8.5	4.5	20	0.95	0.08	8.0	0.9
Diag Stago STA Neoplastine CI+										
RAL Clot-SP	11	4.92	0.35	7.1	4.8	11	0.95	0.05	5.5	1.0
HUMAN HemoStat										
Thromboplastin - SI										
All Coagulation Instruments	14	5.78	1.44	24.9	5.3	14	1.00	0.18	18.4	1.0
IL TEST PT-FIB Recombinant										
IL ACL, all models	40	4.23	0.35	8.2	4.2	41	0.93	0.07	7.6	0.9
TECLOT PT										
Coatron M2 / M4	12	5.57	2.55	45.8	5.4	12	1.00	0.18	18.1	1.0
Wiener Lab Soluplastin										
All Coagulation Instruments	5	4.66	0.94	20.3	4.3	5	3.02	4.46	147.7	1.1

	Specimen CG-3					Specimen CG-4				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	153	1.37	0.16	11.3	1.4	153	1.11	0.14	12.5	1.1
bioMerieux Simplastin Excel S										
bioMerieux Thrombotimer	8	1.42	0.09	6.2	1.5	8	1.20	0.12	10.0	1.2
All Coagulation Instruments	21	1.43	0.11	7.7	1.4	21	1.24	0.14	11.3	1.2
Dade Innovin										
Sysmex CA-1000/1500	6	1.28	0.10	7.7	1.3	6	1.05	0.05	5.2	1.1
Sysmex CA-500	5	1.32	0.08	6.3	1.3	5	1.06	0.09	8.4	1.1
All Coagulation Instruments	13	1.30	0.09	7.0	1.3	13	1.05	0.07	6.3	1.1
Dade Thromborel S										
Sysmex CA-1000/1500	5	1.28	0.11	8.6	1.3	5	1.22	0.04	3.7	1.2
Sysmex CA-500	8	1.24	0.17	13.6	1.2	8	1.35	0.63	46.7	1.2
All Coagulation Instruments	22	1.27	0.13	10.1	1.3	21	1.15	0.08	7.1	1.2
Diag Stago STA Neoplastine CI+										
RAL Clot-SP	11	1.38	0.08	5.4	1.4	11	1.15	0.05	4.5	1.2
HUMAN HemoStat										
Thromboplastin - SI										
All Coagulation Instruments	15	1.36	0.23	17.1	1.3	14	1.15	0.21	18.0	1.1
IL TEST PT-FIB Recombinant										
IL ACL, all models	42	1.43	0.13	8.9	1.4	41	1.00	0.08	7.7	1.0
TECLOT PT										
Coatron M2 / M4	12	1.57	0.45	28.5	1.4	12	1.18	0.22	19.0	1.2
Wiener Lab Soluplastin										
All Coagulation Instruments	5	1.46	0.11	7.8	1.5	5	1.16	0.11	9.8	1.2

PROTHROMBIN TIME-INTERNATIONAL NORMALIZED RATIO (INR)

Specimen CG-5

<u>Reagent/Instruments</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	151	2.86	0.46	16.0	2.9
bioMerieux Simplastin Excel S					
bioMerieux Thrombotimer	8	2.78	0.33	11.8	2.9
All Coagulation Instruments	21	2.91	0.47	16.2	2.8
Dade Innovin					
Sysmex CA-1000/1500	6	2.48	0.24	9.7	2.6
Sysmex CA-500	5	2.48	0.20	8.3	2.4
All Coagulation Instruments	13	2.47	0.21	8.7	2.5
Dade Thromborel S					
Sysmex CA-1000/1500	5	2.98	0.23	7.7	3.0
Sysmex CA-500	8	2.52	0.65	25.6	2.8
All Coagulation Instruments	21	2.89	0.27	9.3	2.9
Diag Stago STA Neoplastine CI+					
RAL Clot-SP	11	3.04	0.12	4.0	3.0
HUMAN HemoStat					
Thromboplastin - SI					
All Coagulation Instruments	14	3.45	0.91	26.2	3.1
IL TEST PT-FIB Recombinant					
IL ACL, all models	41	2.79	0.34	12.0	2.8
TECLOT PT					
Coatron M2 / M4	11	2.90	0.83	28.7	2.8
Wiener Lab Soluplastin					
All Coagulation Instruments	5	3.10	0.50	16.3	3.1

ACTIVATED PARTIAL THROMBOPLASTIN (seconds)

Specimen CG-5

<u>Reagent/Instruments</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	142	51.0	10.5	20.5	49
bioMerieux autoAPTT Reagent					
bioMerieux Thrombotimer	6	53.0	4.5	8.5	53
All Coagulation Instruments	17	52.2	5.1	9.8	53
Dade Actin FS					
All Coagulation Instruments	8	73.8	8.1	11.0	73
Dade Actin FSL					
Sysmex CA-500	6	45.2	6.6	14.7	48
All Coagulation Instruments	17	48.5	5.6	11.5	49
Dade Actin					
Sysmex CA-500	6	58.3	16.5	28.2	65
All Coagulation Instruments	11	62.6	13.2	21.1	65
HUMAN HemoStat aPTT - EL					
All Coagulation Instruments	14	49.8	3.0	6.1	49
IL TEST APTT-SP					
IL ACL, all models	37	45.5	3.4	7.5	45
TECLOT APTT					
Coatron M2 / M4	9	41.8	4.6	11.0	40

FIBRINOGEN (mg/dL)

Specimen CG-1

Specimen CG-2

<u>Reagent/Instruments</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	79	352.5	47.5	13.5	359	80	284.7	33.8	11.9	279
bioMerieux Fibriquik										
All Coagulation Instruments	6	343.3	48.5	14.1	364	5	296.6	44.8	15.1	311
Dade Fibrinogen Set										
Sysmex CA-1000/1500	4	-	-	-	360	5	273.6	27.4	10.0	274
Sysmex CA-500	10	314.9	38.5	12.2	325	10	254.3	40.9	16.1	259
All Coagulation Instruments	19	319.9	33.5	10.5	315	19	266.3	23.7	8.9	259
HUMAN HemoStat Fibrinogen										
All Coagulation Instruments	7	357.0	58.6	16.4	383	7	296.3	46.0	15.5	298
IL TEST PT Fibrinogen										
IL ACL, all models	5	376.0	60.1	16.0	369	5	294.8	23.9	8.1	288
IL TEST PT-FIB Recombinant										
IL ACL, all models	31	372.8	39.9	10.7	380	34	287.0	31.5	11.0	280

Specimen CG-3

Specimen CG-4

All Method	77	120.1	17.7	14.7	118	77	514.9	80.2	15.6	517
Dade Fibrinogen Set										
Sysmex CA-1000/1500	5	109.4	12.5	11.4	103	5	433.2	27.2	6.3	430
Sysmex CA-500	10	112.2	11.3	10.1	113	8	426.9	27.8	6.5	438
All Coagulation Instruments	19	111.8	12.8	11.5	110	18	434.6	35.6	8.2	438
HUMAN HemoStat Fibrinogen										
All Coagulation Instruments	5	111.0	17.6	15.8	115	5	561.4	109.6	19.5	628
IL TEST PT Fibrinogen										
IL ACL, all models	5	128.2	23.6	18.4	122	5	542.4	41.4	7.6	562
IL TEST PT-FIB Recombinant										
IL ACL, all models	35	123.2	16.2	13.2	121	35	549.4	57.1	10.4	559

FIBRINOGEN (mg/dL)

Specimen CG-5

<u>Reagent/Instruments</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method bioMerieux Fibriquik	80	308.4	47.9	15.5	310
All Coagulation Instruments Dade Fibrinogen Set	6	310.3	45.1	14.5	328
Sysmex CA-1000/1500	5	285.4	35.6	12.5	286
Sysmex CA-500	10	255.9	36.8	14.4	267
All Coagulation Instruments HUMAN HemoStat Fibrinogen	20	265.0	34.9	13.2	267
All Coagulation Instruments IL TEST PT Fibrinogen	6	296.8	34.3	11.6	308
IL ACL, all models	5	334.8	36.1	10.8	320
IL TEST PT-FIB Recombinant IL ACL, all models	33	334.2	43.4	13.0	333

Urinalysis

URINALYSIS DIPSTICK-SPECIFIC GRAVITY

Specimen UA-1

<u>Method</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	149	1.0161	0.0049	0.5	1.015
Arkray Aution Sticks	11	1.0235	0.0048	0.5	1.022
Bayer Clinitek 50	7	1.0150	0.0029	0.3	1.015
Bayer Clinitek 500	19	1.0200	0.0000	0.0	1.020
Bayer Reagent Strips	6	1.0142	0.0038	0.4	1.015
Roche (BMC) Chemstrips	26	1.0122	0.0027	0.3	1.010
Roche Miditron	11	1.0141	0.0059	0.6	1.015
Roche Urisys	19	1.0145	0.0037	0.4	1.015
UriScan Reagent Strips	17	1.0162	0.0028	0.3	1.015

URINALYSIS DIPSTICK–pH

Specimen UA-1

Participant Results

<u>Method</u>	<u>3.5 or less</u>	<u>4.0</u>	<u>5.0</u>	<u>5.5</u>	<u>6.0</u>	<u>6.5</u>	<u>7.0</u>	<u>7.5</u>	<u>8.0</u>	<u>8.5</u>	<u>9.0</u>
ALL METHODS	-	-	-	-	1	2	108	41	4	1	-
Arkray Aution Jet	-	-	-	-	-	-	4	-	-	-	-
Arkray Aution Sticks	-	-	-	-	-	-	10	1	-	-	-
Arkray PocketChem UA	-	-	-	-	-	1	-	1	-	-	-
Bayer Clinitek 50	-	-	-	-	-	-	1	6	-	-	-
Bayer Clinitek 500	-	-	-	-	-	-	4	16	-	-	-
Bayer Clinitek Atlas	-	-	-	-	-	-	1	1	-	-	-
Bayer Clinitek Status	-	-	-	-	-	-	-	1	-	-	-
Bayer Reagent Strips	-	-	-	-	1	-	-	6	-	-	-
Iris Diagnostics iChem 100	-	-	-	-	-	-	2	-	2	-	-
Iris Diagnostics vChem Urine Strips	-	-	-	-	-	-	-	1	-	-	-
Quidel QuickVue UrinChek	-	-	-	-	-	-	1	-	-	-	-
Roche (BMC) Chemstrips	-	-	-	-	-	-	25	-	2	-	-
Roche (BMC) Criterion Analyzer	-	-	-	-	-	-	2	-	-	-	-
Roche (BMC) Mini UA	-	-	-	-	-	-	2	-	-	-	-
Roche Mditron	-	-	-	-	-	1	9	-	-	1	-
Roche Urisys	-	-	-	-	-	-	20	-	-	-	-
Roche(BMC) SuperUA/ChemstripUA	-	-	-	-	-	-	4	-	-	-	-
UriScan Pro	-	-	-	-	-	-	1	-	-	-	-
UriScan Reagent Strips	-	-	-	-	-	-	17	1	-	-	-

URINALYSIS DIPSTICK–PROTEIN QUALITATIVE

Specimen UA-1

Participant Results

<u>Method</u>	<u>Negative</u>	<u>Trace</u>	<u>30mg/dL (1+)</u>	<u>100 mg/dL (2+)</u>	<u>300-500mg/dL (3+)</u>	<u>≥1000mg/dL (4+)</u>
ALL METHODS	2	-	1	124	27	2
Arkray Aution Jet	-	-	-	3	1	-
Arkray Aution Sticks	-	-	-	10	1	-
Arkray PocketChem UA	-	-	-	2	-	-
Bayer Clinitek 50	-	-	-	1	6	-
Bayer Clinitek 500	-	-	-	16	3	-
Bayer Clinitek Atlas	-	-	-	1	1	-
Bayer Clinitek Status	-	-	-	-	1	-
Bayer Reagent Strips	-	-	-	3	3	1
Iris Diagnostics iChem 100	-	-	-	4	-	-
Iris Diagnostics vChem Urine Strips	-	-	-	1	-	-
Quidel QuickVue UrinChek	-	-	-	1	-	-
Roche (BMC) Chemstrips	-	-	-	24	3	-
Roche (BMC) Criterion Analyzer	-	-	-	2	-	-
Roche (BMC) Mini UA	-	-	-	2	-	-
Roche Mditron	1	-	-	8	2	-
Roche Urisys	-	-	-	17	2	1
Roche(BMC) SuperUA/ChemstripUA	-	-	-	4	-	-
UriScan Pro	-	-	-	1	-	-
UriScan Reagent Strips	-	-	-	16	2	-

URINALYSIS DIPSTICK–GLUCOSE OR REDUCING SUBSTANCE

Specimen UA-1

<u>Method</u>	<i>Participant Results</i>							
	<u>Negative</u>	<u>50-100 mg/dL (Trace)</u>	<u>150 mg/dL</u>	<u>250 mg/dL</u>	<u>500 mg/dL</u>	<u>1000 mg/dL</u>	<u>>1000 mg/dL</u>	<u>≥2000 mg/dL</u>
ALL METHODS	154	1	-	-	-	1	-	-
Arkray Aution Jet	4	-	-	-	-	-	-	-
Arkray Aution Sticks	11	-	-	-	-	-	-	-
Arkray PocketChem UA	2	-	-	-	-	-	-	-
Bayer Clinitek 50	7	-	-	-	-	-	-	-
Bayer Clinitek 500	18	1	-	-	-	-	-	-
Bayer Clinitek Atlas	2	-	-	-	-	-	-	-
Bayer Clinitek Status	1	-	-	-	-	-	-	-
Bayer Reagent Strips	7	-	-	-	-	-	-	-
Iris Diagnostics iChem 100	4	-	-	-	-	-	-	-
Iris Diagnostics vChem Urine Strips	1	-	-	-	-	-	-	-
Quidel QuickVue UrinChek	1	-	-	-	-	-	-	-
Roche (BMC) Chemstrips	27	-	-	-	-	-	-	-
Roche (BMC) Criterion Analyzer	2	-	-	-	-	-	-	-
Roche (BMC) Mini UA	2	-	-	-	-	-	-	-
Roche Miditron	10	-	-	-	-	1	-	-
Roche Urisys	20	-	-	-	-	-	-	-
Roche(BMC) SuperUA/ChemstripUA	4	-	-	-	-	-	-	-
UriScan Pro	1	-	-	-	-	-	-	-
UriScan Reagent Strips	18	-	-	-	-	-	-	-

URINALYSIS DIPSTICK–KETONES

Specimen UA-1

<u>Method</u>	<i>Participant Results</i>				
	<u>Negative</u>	<u>Trace (5 mg/dL)</u>	<u>Small (1+, 15 mg/dL)</u>	<u>Moderate (2+, 40 mg/dL)</u>	<u>Large (3+, 80 mg/dL)</u>
ALL METHODS	155	1	-	1	-
Arkray Aution Jet	4	-	-	-	-
Arkray Aution Sticks	11	-	-	-	-
Arkray PocketChem UA	2	-	-	-	-
Bayer Clinitek 50	7	-	-	-	-
Bayer Clinitek 500	20	-	-	-	-
Bayer Clinitek Atlas	2	-	-	-	-
Bayer Clinitek Status	1	-	-	-	-
Bayer Reagent Strips	8	-	-	-	-
Iris Diagnostics iChem 100	3	-	-	-	-
Iris Diagnostics vChem Urine Strips	1	-	-	-	-
Quidel QuickVue UrinChek	1	-	-	-	-
Roche (BMC) Chemstrips	27	-	-	-	-
Roche (BMC) Criterion Analyzer	2	-	-	-	-
Roche (BMC) Mini UA	2	-	-	-	-
Roche Miditron	10	-	-	1	-
Roche Urisys	20	-	-	-	-
Roche(BMC) SuperUA/ChemstripUA	4	-	-	-	-
UriScan Pro	1	-	-	-	-
UriScan Reagent Strips	18	-	-	-	-

URINALYSIS DIPSTICK–BILIRUBIN

Specimen UA-1

Participant Results

<u>Method</u>	<u>Negative</u>	<u>Small (1+)</u>	<u>Moderate (2+)</u>	<u>Large (3+)</u>
ALL METHODS	156	1	-	-
Arkray Aution Jet	4	-	-	-
Arkray Aution Sticks	11	-	-	-
Arkray PocketChem UA	2	-	-	-
Bayer Clinitek 50	7	-	-	-
Bayer Clinitek 500	20	-	-	-
Bayer Clinitek Atlas	2	-	-	-
Bayer Clinitek Status	1	-	-	-
Bayer Reagent Strips	8	-	-	-
Iris Diagnostics iChem 100	4	-	-	-
Iris Diagnostics vChem Urine Strips	1	-	-	-
Quidel QuickVue UrinChek	1	-	-	-
Roche (BMC) Chemstrips	27	-	-	-
Roche (BMC) Criterion Analyzer	2	-	-	-
Roche (BMC) Mini UA	2	-	-	-
Roche Miditron	10	1	-	-
Roche Urisys	20	-	-	-
Roche(BMC) SuperUA/ChemstripUA	4	-	-	-
UriScan Pro	1	-	-	-
UriScan Reagent Strips	18	-	-	-

URINALYSIS DIPSTICK–UROBILINOGEN

Specimen UA-1

Participant Results

<u>Method</u>	<u>0.2/Normal mg/dL</u>	<u>1.0 mg/dL</u>	<u>2.0 mg/dL</u>	<u>4.0 mg/dL</u>	<u>>8.0 mg/dL</u>
ALL METHODS	156	-	-	-	-
Arkray Aution Jet	4	-	-	-	-
Arkray Aution Sticks	11	-	-	-	-
Arkray PocketChem UA	2	-	-	-	-
Bayer Clinitek 50	7	-	-	-	-
Bayer Clinitek 500	20	-	-	-	-
Bayer Clinitek Atlas	2	-	-	-	-
Bayer Clinitek Status	1	-	-	-	-
Bayer Reagent Strips	8	-	-	-	-
Iris Diagnostics iChem 100	4	-	-	-	-
Iris Diagnostics vChem Urine Strips	1	-	-	-	-
Quidel QuickVue UrinChek	1	-	-	-	-
Roche (BMC) Chemstrips	27	-	-	-	-
Roche (BMC) Criterion Analyzer	2	-	-	-	-
Roche (BMC) Mini UA	2	-	-	-	-
Roche Miditron	10	-	-	-	-
Roche Urisys	20	-	-	-	-
Roche(BMC) SuperUA/ChemstripUA	4	-	-	-	-
UriScan Pro	1	-	-	-	-
UriScan Reagent Strips	18	-	-	-	-

URINALYSIS DIPSTICK–BLOOD/HEMOGLOBIN

Specimen UA-1

Participant Results

<u>Method</u>	<u>Negative</u>	<u>Trace</u>	<u>Small (1+)</u>	<u>Moderate (2+)</u>	<u>Large (3+)</u>
ALL METHODS	1	2	1	9	145
Arkray Aution Jet	-	-	-	1	3
Arkray Aution Sticks	-	-	-	3	8
Arkray PocketChem UA	-	-	-	-	2
Bayer Clinitek 50	-	-	-	1	7
Bayer Clinitek 500	-	-	-	-	19
Bayer Clinitek Atlas	-	-	-	-	2
Bayer Clinitek Status	-	-	-	-	1
Bayer Reagent Strips	-	-	-	-	8
Iris Diagnostics iChem 100	-	1	-	-	3
Iris Diagnostics vChem Urine Strips	-	-	-	-	1
Quidel QuickVue UrinChek	-	-	-	-	1
Roche (BMC) Chemstrips	-	-	-	1	26
Roche (BMC) Criterion Analyzer	-	-	-	-	2
Roche (BMC) Mini UA	-	-	-	-	2
Roche Miditron	1	-	-	1	9
Roche Urisys	-	-	-	-	20
Roche(BMC) SuperUA/ChemstripUA	-	-	-	-	4
UriScan Pro	-	-	-	-	1
UriScan Reagent Strips	-	-	-	1	17

URINALYSIS DIPSTICK–LEUKOCYTE ESTERASE

Specimen UA-1

Participant Results

<u>Method</u>	<u>Negative</u>	<u>Trace</u>	<u>Small (1+)</u>	<u>Moderate (2+)</u>	<u>Large (3+)</u>
ALL METHODS	155	1	-	-	1
Arkray Aution Jet	4	-	-	-	-
Arkray Aution Sticks	11	-	-	-	-
Arkray PocketChem UA	2	-	-	-	-
Bayer Clinitek 50	7	-	-	-	-
Bayer Clinitek 500	20	-	-	-	-
Bayer Clinitek Atlas	2	-	-	-	-
Bayer Clinitek Status	1	-	-	-	-
Bayer Reagent Strips	8	-	-	-	-
Iris Diagnostics iChem 100	4	-	-	-	-
Iris Diagnostics vChem Urine Strips	1	-	-	-	-
Quidel QuickVue UrinChek	1	-	-	-	-
Roche (BMC) Chemstrips	27	-	-	-	-
Roche (BMC) Criterion Analyzer	2	-	-	-	-
Roche (BMC) Mini UA	2	-	-	-	-
Roche Miditron	10	-	-	-	1
Roche Urisys	20	-	-	-	-
Roche(BMC) SuperUA/ChemstripUA	4	-	-	-	-
UriScan Pro	1	-	-	-	-
UriScan Reagent Strips	17	1	-	-	-

URINALYSIS DIPSTICK–NITRITE

Specimen UA-1

Participant Results

<u>Method</u>	<u>Negative</u>	<u>Positive</u>
ALL METHODS	154	3
Arkray Aution Jet	4	-
Arkray Aution Sticks	11	-
Arkray PocketChem UA	2	-
Bayer Clinitek 50	7	-
Bayer Clinitek 500	20	-
Bayer Clinitek Atlas	2	-
Bayer Clinitek Status	1	-
Bayer Reagent Strips	8	-
Iris Diagnostics iChem 100	4	-
Iris Diagnostics vChem Urine Strips	1	-
Quidel QuickVue UrinChek	1	-
Roche (BMC) Chemstrips	25	1
Roche (BMC) Criterion Analyzer	2	-
Roche (BMC) Mini UA	2	-
Roche Mditron	10	1
Roche Urisys	19	1
Roche(BMC) SuperUA/ChemstripUA	4	-
UriScan Pro	1	-
UriScan Reagent Strips	18	-

URINALYSIS –MICROALBUMIN (dipstick only)

Specimen UA-1

Participant Results

<u>Method</u>	<u>Negative</u>	<u>10 mg/L(Pos)</u>	<u>20/30 mg/L</u>	<u>50 mg/L (+)</u>	<u>80 mg/L</u>	<u>100 mg/L (++)</u>	<u>150 mg/L</u>
ALL METHODS	1	-	-	-	1	3	-
Roche (BMC) Micral - 1 minute	-	-	-	-	-	1	-
Bayer Clinitek Microalbumin	-	-	-	-	-	-	-
Roche Mditron	-	-	-	-	-	-	-

URINALYSIS –URINE hCG

Specimen UA-1

Participant Results

<u>Method</u>	<u>Negative</u>	<u>Positive</u>
ALL METHODS	1	12
Acon Laboratories	-	3
bioMerieux VIKIA hCG-D	-	6

ANTIMICROBIAL SUSCEPTIBILITY TESTING

Specimen SUS-1

<i>Antimicrobial</i>	-----Disk Diffusion-----				-----MIC-----				<i>Acceptable (%)</i>
	<i>Interpretative category data</i>				<i>Interpretative category data</i>				
	<i>Labs</i>	<i>S</i>	<i>I</i>	<i>R</i>	<i>Labs</i>	<i>S</i>	<i>I</i>	<i>R</i>	
Amikacin	10	9	1	-	32	32	-	-	98.57%
Amoxicillin/Clavulanate	6	5	-	1	28	27	-	1	96.49%
Ampicillin	8	5	1	2	36	34	1	1	91.78%
Ampicillin/Sulbactam	10	9	-	1	25	25	-	-	98.25%
Aztreonam	7	7	-	-	4	4	-	-	100%
Cefaclor	1	1	-	-	-	-	-	-	100%
Cefazolin	1	1	-	-	20	20	-	-	100%
Cefepime	5	5	-	-	28	28	-	-	100%
Cefixime	-	-	-	-	1	1	-	-	100%
Cefoperazone	2	2	-	-	-	-	-	-	100%
Cefotaxime	8	8	-	-	24	24	-	-	100%
Cefotetan	-	-	-	-	2	2	-	-	100%
Cefoxitin	3	3	-	-	5	5	-	-	100%
Ceftazidime	6	5	-	1	28	28	-	-	98.25%
Ceftizoxime	-	-	-	-	1	1	-	-	100%
Ceftriaxone	8	8	-	-	22	22	-	-	100%
Cefuroxime	3	3	-	-	28	27	-	1	95.92%
Cephadrine	2	1	-	1	-	-	-	-	Not graded ¹
Cephalexin	-	-	-	-	3	3	-	-	83.33%
Cephalothin	9	6	1	2	34	31	2	1	85.25%
Ciprofloxacin	14	14	-	-	40	40	-	-	100%
Clindamycin	2	-	-	2	1	1	-	-	Not graded ¹
Ertapenem	1	1	-	-	-	-	-	-	100%
Fosfomycin	3	3	-	-	5	5	-	-	100%
Gentamicin	12	11	1	-	39	38	-	1	97.67%
Imipenem	6	6	-	-	38	38	-	-	100%
Kanamycin	1	1	-	-	1	1	-	-	100%
Levofloxacin	2	2	-	-	23	23	-	-	100%
Linezolid	2	-	-	2	-	-	-	-	100%
Meropenem	5	5	-	-	10	10	-	-	100%
Methicillin	1	-	-	1	-	-	-	-	100%
Nalidixic Acid	9	9	-	-	12	12	-	-	100%
Netilmicin	1	1	-	-	2	2	-	-	100%
Nitrofurantoin	14	12	2	-	36	36	-	-	97.62%
Norfloxacin	11	11	-	-	14	14	-	-	100%
Ofloxacin	2	2	-	-	-	-	-	-	100%
Oxacillin	2	-	-	2	-	-	-	-	100%
Penicillin	2	-	-	2	2	2	-	-	Not graded ¹
Piperacillin	2	2	-	-	8	8	-	-	100%
Piperacillin/Tazobactam	4	4	-	-	32	32	-	-	100%
Rifampin	2	-	-	2	-	-	-	-	100%
Sulfisoxazole	-	-	-	-	1	1	-	-	100%
Tetracycline	2	2	-	-	19	19	-	-	100%
Ticarcillin	-	-	-	-	2	2	-	-	100%
Ticarcillin/Clavulanate	-	-	-	-	15	15	-	-	100%
Tobramycin	1	1	-	-	28	27	-	1	97.83%
Trimethoprim	1	1	-	-	7	7	-	-	100%
Trimethoprim/Sulfamethoxazole	13	13	-	-	41	40	-	1	97.56%
Vancomycin	2	-	-	2	-	-	-	-	100%

Organism present in specimen SUS-1: *Escherichia coli*.

¹ This is an ungraded challenge due to less than 80% participant consensus.

PARASITOLOGY (PA Specimens)

Specimen PA-1

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
No Parasite seen	1	50.00%	Not graded
Protozoan seen but no ID	1	50.00%	

Parasite present in specimen PA-1: No parasite seen. This is an ungraded challenge due to less than 80% participant consensus.

Specimen PA-2

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Protozoan seen but no ID	1	100%	Acceptable

Parasite present in specimen PA-2: *Entamoeba coli*.

Specimen PA-3

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
No parasite seen	2	100%	Acceptable

Parasite present in specimen PA-3: No parasite seen.

Specimen PA-4

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Giardia lamblia	1	33.33%	Not graded
Parasite seen but no ID	1	33.33%	
No parasite seen	1	33.33%	

Parasite present in specimen PA-4: *Giardia lamblia*. This is an ungraded challenge due to less than 80% participant consensus.

Specimen PA-5

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Plasmodium malariae	1	100%	Acceptable

Parasite present in specimen PA-5: *Plasmodium malariae*.

PARASITOLOGY (FP Specimens)

Specimen FP-1

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
No parasite seen	108	89.26%	Acceptable
Endolimax nana	4	3.31%	
Chilomastix mesnili	2	1.65%	
Cryptosporidium sp., oocysts	1	0.83%	
Enterobius vermicularis eggs	1	0.83%	
Clonorchis sinensis	1	0.83%	
Isospora belli oocysts	1	0.83%	
Trichuris trichiura eggs	1	0.83%	
Blastocystis hominis	1	0.83%	

Parasite present in specimen FP-1: No parasite seen.

Specimen FP-2

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Clonorchis sinensis	67	37.43%	Not graded
Endolimax nana	28	15.64%	
Chilomastix mesnili	24	13.41%	
No parasite seen	9	5.03%	
Entamoeba histolytica	8	4.47%	
Fasciola hepatica eggs	5	2.79%	
Giardia lamblia	5	2.79%	
Entamoeba coli	5	2.79%	
Paragonimus westermani eggs	5	2.79%	
Trichuris trichiura eggs	4	2.23%	
Diphyllobothrium latum	4	2.23%	
Ascaris lumbricoides eggs	4	2.23%	
Blastocystis hominis	3	1.68%	
Parasite egg seen but no ID	3	1.68%	
Other parasite seen but no ID	1	0.56%	
Hookworm	1	0.56%	
Hymenolepis diminuta eggs	1	0.56%	
Isospora belli oocysts	1	0.56%	
Entamoeba hartmanni	1	0.56%	

Parasite present in specimen FP-2: *Clonorchis sinensis*. This is an ungraded challenge due to less than 80% participant consensus.

PARASITOLOGY (FP Specimens)

Specimen FP-3

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Schistosoma haematobium egg	85	68.55%	Not graded
Schistosoma sp. eggs, NOS	10	8.06%	
No parasite seen	18	14.52%	
Fasciola hepatica eggs	2	1.61%	
Clonorchis sinensis	2	1.61%	
Ascaris lumbricoides	2	1.61%	
Schistosoma mansoni eggs	2	1.61%	
Trichuris trichiura eggs	1	0.81%	
Endolimax nana	1	0.81%	
Entamoeba coli	1	0.81%	

Parasite present in specimen FP-3: *Schistosoma haematobium* eggs. This is an ungraded challenge due to less than 80% participant consensus.

Specimen FP-4

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Hymenolepis nana eggs	84	62.69%	Not graded
Taenia sp. eggs	14	10.45%	
Hymenolepis diminuta eggs	12	8.96%	
No parasite seen	8	5.97%	
Ascaris lumbricoides eggs	6	4.48%	
Endolimax nana	2	1.49%	
Parasite seen but no ID	2	1.49%	
Parasite larva seen but no ID	1	0.75%	
Trichostrongylus sp. eggs	1	0.75%	
Entamoeba histolytica	1	0.75%	
Clonorchis sinensis	1	0.75%	
Schistosoma sp. eggs, NOS	1	0.75%	
Strongyloides stercoralis larvae	1	0.75%	

Parasite present in specimen FP-4: *Hymenolepis nana* eggs. This is an ungraded challenge due to less than 80% participant consensus.

Specimen FP-5

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Plasmodium falciparum	80	61.07%	Not graded
Plasmodium vivax	30	22.90%	
Plasmodium sp., NOS	17	12.98%	
Plasmodium sp., not falciparum	2	1.53%	
Fasciola hepatica eggs	1	0.76%	
Plasmodium malariae	1	0.76%	

Parasite present in specimen FP-5: *Plasmodium falciparum*. This is an ungraded challenge due to less than 80% participant consensus.

Syphilis Serology—Qualitative: VDRL Slide

<u>Method</u>	Specimen SY-1			Specimen SY-2			Specimen SY-3		
	<u>Reactive</u>	<u>Weakly Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Weakly Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Weakly Reactive</u>	<u>Non-Reactive</u>
ALL METHODS	8	1	-	-	-	9	-	-	9
BioBacter	1	-	-	-	-	1	-	-	1
Omega Diagnostics	-	1	-	-	-	1	-	-	1
Wiener Lab	6	-	-	-	-	6	-	-	6

<u>Method</u>	Specimen SY-4			Specimen SY-5		
	<u>Reactive</u>	<u>Weakly Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Weakly Reactive</u>	<u>Non-Reactive</u>
ALL METHODS	9	-	-	9	-	-
BioBacter	1	-	-	1	-	-
Omega Diagnostics	1	-	-	1	-	-
Wiener Lab	6	-	-	6	-	-

Syphilis Serology—Quantitative: VDRL Slide Titer

<u>Specimen/Method</u>	<u>0 dils</u>	<u>1 dil</u>	<u>2 dils</u>	<u>4 dils</u>	<u>8 dils</u>	<u>16 dils</u>	<u>32 dils</u>	<u>>32 dils</u>
Specimen SY-1								
ALL METHODS	5	1	2	-	-	-	-	-
BioBacter	-	1	-	-	-	-	-	-
Omega Diagnostics	1	-	-	-	-	-	-	-
Wiener Lab	4	-	2	-	-	-	-	-
Specimen SY-4								
ALL METHODS	1	1	4	2	-	-	-	-
BioBacter	-	-	1	-	-	-	-	-
Omega Diagnostics	-	1	-	-	-	-	-	-
Wiener Lab	1	-	3	2	-	-	-	-
Specimen SY-5								
ALL METHODS	3	1	2	1	-	-	-	-
BioBacter	-	1	-	-	-	-	-	-
Omega Diagnostics	1	-	-	-	-	-	-	-
Wiener Lab	2	-	2	1	-	-	-	-

Syphilis Serology—Qualitative: MHA-TP

<u>Method</u>	Specimen SY-1		Specimen SY-2		Specimen SY-3	
	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>
ALL METHODS	7	1	-	8	-	8
Biokit	1	-	-	1	-	1
bioMerieux	1	-	-	1	-	1
Human	1	-	-	1	-	1
Serodia	2	1	-	3	-	3

<u>Method</u>	Specimen SY-4		Specimen SY-5	
	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>
ALL METHODS	8	-	8	-
Biokit	1	-	1	-
bioMerieux	1	-	1	-
Human	1	-	1	-
Serodia	3	-	3	-

Syphilis Serology—Qualitative: FTA-ABS (*Treponema pallidum* Antibodies)

<u>Method</u>	Specimen SY-1		Specimen SY-2		Specimen SY-3	
	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>
ALL METHODS	4	-	-	4	-	4
bioMerieux	2	-	-	2	-	2
Bio-Rad Evolis	1	-	-	1	-	1

<u>Method</u>	Specimen SY-4		Specimen SY-5	
	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>
ALL METHODS	4	-	4	-
bioMerieux	2	-	2	-
Bio-Rad Evolis	1	-	1	-

Syphilis Serology—Qualitative: RPR

<u>Method</u>	Specimen SY-1		Specimen SY-2		Specimen SY-3	
	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>
ALL METHODS	16	2	-	18	1	17
Abbott Syfacard-R	2	-	-	2	-	2
Becton Dickinson	1	1	-	2	-	2
Biokit	1	-	-	1	-	1
bioMerieux	2	-	-	2	-	2
Immunostics Inc.	1	-	-	1	-	1
Omega Diagnostics	4	-	-	4	1	3
Serodia	1	-	-	1	-	1
SPINREACT	1	-	-	1	-	1
Wiener Lab	-	1	-	1	-	1

	Specimen SY-4		Specimen SY-5	
	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>
ALL METHODS	18	-	17	1
Abbott Syfacard-R	2	-	2	-
Becton Dickinson	2	-	1	1
Biokit	1	-	1	-
bioMerieux	2	-	2	-
Immunostics Inc.	1	-	1	-
Omega Diagnostics	4	-	4	-
Serodia	1	-	1	-
SPINREACT	1	-	1	-
Wiener Lab	1	-	1	-

Syphilis Serology—Quantitative: RPR (Titer)

<u>Specimen/Method</u>	<u>1</u>	<u>2</u>	<u>4</u>	<u>8</u>	<u>16</u>	<u>32</u>	<u>64</u>	<u>>64</u>
Specimen SY-1								
ALL METHODS	7	1	-	-	1	-	1	-
Abbott Syfacard-R	1	1	-	-	-	-	-	-
bioMerieux	2	-	-	-	-	-	-	-
Immunostics Inc.	1	-	-	-	-	-	-	-
Omega Diagnostics	-	-	-	-	1	-	-	-
Serodia	-	-	-	-	-	-	1	-
SPINREACT	1	-	-	-	-	-	-	-
Wiener Lab	-	-	-	-	-	-	-	-
Specimen SY-4								
ALL METHODS	2	6	1	-	1	-	1	-
Abbott Syfacard-R	-	1	1	-	-	-	-	-
bioMerieux	-	2	-	-	-	-	-	-
Immunostics Inc.	-	1	-	-	-	-	-	-
Omega Diagnostics	-	-	-	-	1	-	-	-
Serodia	-	-	-	-	-	-	1	-
SPINREACT	-	1	-	-	-	-	-	-
Wiener Lab	1	-	-	-	-	-	-	-
Specimen SY-5								
ALL METHODS	4	4	-	-	1	1	-	-
Abbott Syfacard-R	1	1	-	-	-	-	-	-
bioMerieux	1	1	-	-	-	-	-	-
Immunostics Inc.	1	-	-	-	-	-	-	-
Omega Diagnostics	-	-	-	-	1	-	-	-
Serodia	-	-	-	-	-	1	-	-
SPINREACT	-	1	-	-	-	-	-	-
Wiener Lab	-	1	-	-	-	-	-	-

Viral Markers – Anti-HIV

<u>Method</u>	Specimen VM-1		Specimen VM-2		Specimen VM-3	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	63	1	-	64	64	-
Abbott Architect - IgM	1	-	-	1	1	-
Abbott Architect - Total	6	-	-	6	6	-
Abbott AxSYM - IgG	2	-	-	2	2	-
Abbott AxSYM - Total	13	-	-	13	13	-
Abbott Commander - IgM	1	-	-	1	1	-
Bayer ADVIA Centaur - Total	2	-	-	2	2	-
bioMerieux Vidas - Total	6	-	-	6	6	-
Bio-Rad Evolis	2	-	-	2	2	-
Other Total Method	7	-	-	7	7	-
Roche Cobas CORE	1	-	-	1	1	-
Roche Elecsys - Total	8	1	-	9	9	-
Roche Elecsys 1010/2010	1	-	-	1	1	-
VITROS ECI	1	-	-	1	1	-
VITROS ECI - IgG	1	-	-	1	1	-
VITROS ECI - Total	3	-	-	3	3	-
	Specimen VM-4		Specimen VM-5			
ALL METHODS	2	61	-	63		
Abbott Architect - IgM	-	1	-	1		
Abbott Architect - Total	-	6	-	6		
Abbott AxSYM - IgG	-	1	-	2		
Abbott AxSYM - Total	1	12	-	13		
Abbott Commander - IgM	-	1	-	1		
Bayer ADVIA Centaur - Total	-	2	-	2		
bioMerieux Vidas - Total	-	6	-	6		
Bio-Rad Evolis	-	2	-	2		
Other Total Method	1	6	-	7		
Roche Cobas CORE	-	1	-	1		
Roche Elecsys - Total	-	9	-	8		
Roche Elecsys 1010/2010	-	1	-	1		
VITROS ECI	-	1	-	1		
VITROS ECI - IgG	-	1	-	1		
VITROS ECI - Total	-	3	-	3		

Viral Markers – HAV

<u>Method</u>	Specimen VM-1		Specimen VM-2		Specimen VM-3	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	3	38	-	41	1	39
Abbott Architect - IgG	3	-	-	3	-	3
Abbott AxSYM - IgG	-	4	-	4	-	4
Abbott AxSYM - IgM	-	3	-	3	-	3
Abbott AxSYM - Total	-	6	-	6	-	6
Abbott Commander - IgM	-	1	-	1	-	1
bioMerieux Vidas - IgM	-	6	-	6	-	6
bioMerieux Vidas - Total	-	1	-	1	1	-
DiaSorin - IgM	-	1	-	1	-	1
Other IgG Method	-	1	-	1	-	1
Roche Elecsys - IgM	-	6	-	6	-	6
Roche Elecsys - Total	-	4	-	4	-	4
Roche Elecsys 1010/2010	-	1	-	1	-	1
VITROS ECi - IgM	-	1	-	1	-	1
	Specimen VM-4		Specimen VM-5			
ALL METHODS	-	41	39	1		
Abbott Architect - IgG	-	3	3	-		
Abbott AxSYM - IgG	-	4	4	-		
Abbott AxSYM - IgM	-	3	3	-		
Abbott AxSYM - Total	-	6	6	-		
Abbott Commander - IgM	-	1	1	-		
bioMerieux Vidas - IgM	-	6	6	-		
bioMerieux Vidas - Total	-	1	1	-		
DiaSorin - IgM	-	1	1	-		
Other IgG Method	-	1	1	-		
Roche Elecsys - IgM	-	6	5	-		
Roche Elecsys - Total	-	4	4	-		
Roche Elecsys 1010/2010	-	1	-	1		
VITROS ECi - IgM	-	1	1	-		

Viral Markers – HBeAg

<u>Method</u>	Specimen VM-1		Specimen VM-2		Specimen VM-3	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	23	-	23	-	23
Abbott Architect - IgG	-	1	-	1	-	1
Abbott AxSYM - IgG	-	1	-	1	-	1
Abbott AxSYM - Total	-	6	-	6	-	6
bioMerieux Vidas - Total	-	2	-	2	-	2
DiaSorin - Total	-	1	-	1	-	1
Other Total Method	-	3	-	3	-	3
Roche Elecsys - Total	-	3	-	3	-	3
VITROS ECi - IgG	-	1	-	1	-	1
VITROS ECi - Total	-	2	-	2	-	2
	Specimen VM-4		Specimen VM-5			
ALL METHODS	2	21	-	23		
Abbott Architect - IgG	-	1	-	1		
Abbott AxSYM - IgG	-	1	-	1		
Abbott AxSYM - Total	-	6	-	6		
bioMerieux Vidas - Total	1	1	-	2		
DiaSorin - Total	-	1	-	1		
Other Total Method	-	3	-	3		
Roche Elecsys - Total	-	3	-	3		
VITROS ECi - IgG	-	1	-	1		
VITROS ECi - Total	1	1	-	2		

Viral Markers – HBsAb

<u>Method</u>	Specimen VM-1		Specimen VM-2		Specimen VM-3	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	45	-	45	-	44
Abbott Architect	-	1	-	1	-	1
Abbott Architect - IgG	-	1	-	1	-	1
Abbott Architect - Total	-	2	-	2	-	2
Abbott AxSYM	-	1	-	1	-	1
Abbott AxSYM - IgG	-	2	-	2	-	2
Abbott AxSYM - IgM	-	1	-	1	-	1
Abbott AxSYM - Total	-	9	-	9	-	9
Abbott Commander - IgM	-	1	-	1	-	1
bioMerieux Vidas - Total	-	1	-	1	-	1
DiaSorin - Total	-	1	-	1	-	1
Other Total Method	-	4	-	4	-	4
Roche Elecsys - IgG	-	3	-	3	-	3
Roche Elecsys - Total	-	5	-	5	-	5
Roche Elecsys 1010/2010	-	2	-	2	-	2
VITROS ECi - IgG	-	1	-	1	-	1
VITROS ECi - Total	-	2	-	2	-	2
	Specimen VM-4		Specimen VM-5			
ALL METHODS	1	44	-	45		
Abbott Architect	-	1	-	1		
Abbott Architect - IgG	-	1	-	1		
Abbott Architect - Total	-	2	-	2		
Abbott AxSYM	-	1	-	1		
Abbott AxSYM - IgG	-	2	-	2		
Abbott AxSYM - IgM	-	1	-	1		
Abbott AxSYM - Total	-	9	-	9		
Abbott Commander - IgM	-	1	-	1		
bioMerieux Vidas - Total	-	1	-	1		
DiaSorin - Total	-	1	-	1		
Other Total Method	1	3	-	4		
Roche Elecsys - IgG	-	3	-	3		
Roche Elecsys - Total	-	5	-	5		
Roche Elecsys 1010/2010	-	2	-	2		
VITROS ECi - IgG	-	1	-	1		
VITROS ECi - Total	-	2	-	2		

Viral Markers – Anti-HBsAg

<u>Method</u>	Specimen VM-1		Specimen VM-2		Specimen VM-3	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	11	54	2	63	65	-
Abbott Architect - IgG	-	1	-	1	1	-
Abbott Architect - IgM	-	1	-	1	1	-
Abbott Architect - Total	-	7	-	7	7	-
Abbott AxSYM - IgG	-	3	-	3	3	-
Abbott AxSYM - Total	7	5	-	12	12	-
Abbott Commander - IgM	-	1	-	1	1	-
Bayer ADVIA Centaur - Total	-	2	-	2	2	-
bioMerieux Vidas - Total	-	6	-	6	6	-
Bio-Rad Evolis	1	-	-	1	1	-
DiaSorin - Total	-	1	-	1	1	-
Other Total Method	2	7	2	7	9	-
Roche Elecsys - Total	-	4	-	4	4	-
Roche Elecsys 1010/2010	-	2	-	2	2	-
VITROS ECi - IgG	-	1	-	1	1	-
VITROS ECi - Total	-	5	-	5	5	-
	Specimen VM-4		Specimen VM-5			
ALL METHODS	63	-	3	62		
Abbott Architect - IgG	1	-	-	1		
Abbott Architect - IgM	1	-	-	1		
Abbott Architect - Total	7	-	-	7		
Abbott AxSYM - IgG	2	-	-	3		
Abbott AxSYM - Total	11	-	-	12		
Abbott Commander - IgM	1	-	-	1		
Bayer ADVIA Centaur - Total	2	-	-	2		
bioMerieux Vidas - Total	6	-	-	6		
Bio-Rad Evolis	1	-	-	1		
DiaSorin - Total	1	-	-	1		
Other Total Method	9	-	1	8		
Roche Elecsys - Total	4	-	-	4		
Roche Elecsys 1010/2010	2	-	-	2		
VITROS ECi - IgG	1	-	-	1		
VITROS ECi - Total	5	-	-	5		

Viral Markers – HCV

<u>Method</u>	Specimen VM-1		Specimen VM-2		Specimen VM-3	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	39	21	-	60	-	60
Abbott Architect - IgG	-	3	-	3	-	3
Abbott Architect - IgM	-	1	-	1	-	1
Abbott Architect - Total	-	4	-	4	-	4
Abbott AxSYM - IgG	2	1	-	3	-	3
Abbott AxSYM - Total	13	-	-	13	-	13
Abbott Commander - IgM	1	-	-	1	-	1
Abbott IMx - Total	2	-	-	2	-	2
Bayer ADVIA Centaur - IgG	1	-	-	1	-	1
Bayer ADVIA Centaur - Total	1	1	-	2	-	2
Bio-Rad Evolis	2	-	-	2	-	2
Other Total Method	3	6	-	9	-	9
Roche Elecsys - Total	1	1	-	2	-	2
VITROS ECi	1	-	-	1	-	1
VITROS ECi - IgG	1	-	-	1	-	1
VITROS ECi - Total	6	-	-	6	-	6
	Specimen VM-4		Specimen VM-5			
ALL METHODS	5	55	-	60		
Abbott Architect - IgG	-	3	-	3		
Abbott Architect - IgM	-	1	-	1		
Abbott Architect - Total	-	4	-	4		
Abbott AxSYM - IgG	-	3	-	3		
Abbott AxSYM - Total	-	13	-	13		
Abbott Commander - IgM	-	1	-	1		
Abbott IMx - Total	-	2	-	2		
Bayer ADVIA Centaur - IgG	-	1	-	1		
Bayer ADVIA Centaur - Total	-	2	-	2		
Bio-Rad Evolis	-	2	-	2		
Other Total Method	2	7	-	9		
Roche Elecsys - Total	1	1	-	2		
VITROS ECi	-	1	-	1		
VITROS ECi - IgG	-	1	-	1		
VITROS ECi - Total	-	6	-	6		

Blood Gases – pH

<u>Method</u>	<u>Specimen BG-1</u>					<u>Specimen BG-2</u>				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	14	7.165	0.012	0.2	7.17	14	6.878	0.021	0.3	6.88
AVL OMNI	5	7.160	0.012	0.2	7.16	5	6.892	0.025	0.4	6.91
<u>Method</u>	<u>Specimen BG-3</u>					<u>Specimen BG-4</u>				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	13	7.156	0.013	0.2	7.15	14	7.409	0.018	0.2	7.40
AVL OMNI	4	-	-	-	7.15	5	7.394	0.009	0.1	7.40
<u>Method</u>	<u>Specimen BG-5</u>									
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>					
All Method	13	7.585	0.028	0.4	7.60					
AVL OMNI	4	-	-	-	7.55					

Blood Gases - pCO₂ (mmHg)

<u>Method</u>	<u>Specimen BG-1</u>					<u>Specimen BG-2</u>				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	14	58.13	2.00	3.4	58.1	14	88.99	4.14	4.6	88.4
AVL OMNI	5	59.18	1.82	3.1	59.7	5	87.58	4.23	4.8	85.6
<u>Method</u>	<u>Specimen BG-3</u>					<u>Specimen BG-4</u>				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	13	70.75	3.00	4.2	69.6	14	43.02	1.61	3.8	43.3
AVL OMNI	4	-	-	-	73.3	5	43.96	1.16	2.6	43.6
<u>Method</u>	<u>Specimen BG-5</u>									
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>					
All Method	13	22.52	1.45	6.4	22.9					
AVL OMNI	4	-	-	-	23.8					

Blood Gases - pO₂ (mmHg)

<u>Method</u>	<u>Specimen BG-1</u>					<u>Specimen BG-2</u>				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	14	109.94	11.38	10.4	112.2	13	40.45	25.99	64.3	33.0
AVL OMNI	5	118.18	13.88	11.7	120.0	5	55.02	29.73	54.0	67.9
<u>Method</u>	<u>Specimen BG-3</u>					<u>Specimen BG-4</u>				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	14	70.22	23.80	33.9	73.3	14	98.94	9.13	9.2	102.9
AVL OMNI	5	86.26	32.77	38.0	83.9	5	103.52	10.40	10.1	105.8
<u>Method</u>	<u>Specimen BG-5</u>									
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>					
All Method	14	135.09	17.70	13.1	136.5					
AVL OMNI	5	127.50	27.38	21.5	125.8					

Blood Gases - Ionized Calcium (mmol/L)

<u>Method</u>	<u>Labs</u>	<u>Specimen BG-1</u>					<u>Specimen BG-2</u>				
		<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	
All Method	10	1.031	0.315	30.5	0.95	10	2.888	0.572	19.8	2.96	
AVL OMNI	6	0.923	0.045	4.9	0.92	6	2.992	0.134	4.5	2.95	

Blood Gases - Chloride (mmol/L)

<u>Method</u>	<u>Labs</u>	<u>Specimen BG-1</u>					<u>Specimen BG-2</u>				
		<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	
All Method	6	86.5	3.3	3.8	87	5	66.6	3.8	5.7	66	
		<u>Specimen BG-3</u>					<u>Specimen BG-4</u>				
All Method	6	77.2	5.6	7.3	76	6	94.0	2.6	2.8	94	
		<u>Specimen BG-5</u>									
All Method	6	117.5	4.0	3.4	116						

Blood Gases - Potassium (mmol/L)

<u>Method</u>	<u>Labs</u>	<u>Specimen BG-1</u>					<u>Specimen BG-2</u>				
		<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	
All Method	7	3.17	0.11	3.5	3.2	7	11.47	1.27	11.1	11.2	
AVL OMNI	5	3.12	0.08	2.7	3.1	5	11.76	1.30	11.1	11.2	
		<u>Specimen BG-3</u>					<u>Specimen BG-4</u>				
All Method	7	1.80	0.13	7.2	1.8	7	4.29	0.07	1.6	4.3	
AVL OMNI	5	1.80	0.16	8.8	1.8	5	4.26	0.05	1.3	4.3	
		<u>Specimen BG-5</u>									
All Method	7	6.39	0.23	3.7	6.3						
AVL OMNI	5	6.44	0.26	4.0	6.3						

Blood Gases - Sodium (mmol/L)

<u>Method</u>	<u>Labs</u>	<u>Specimen BG-1</u>					<u>Specimen BG-2</u>				
		<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	
All Method	7	130.7	2.8	2.1	132	7	84.9	4.3	5.1	87	
AVL OMNI	5	130.0	2.8	2.2	132	5	84.2	4.8	5.7	87	
		<u>Specimen BG-3</u>					<u>Specimen BG-4</u>				
All Method	7	110.0	2.8	2.6	112	7	127.9	7.3	5.7	130	
AVL OMNI	5	110.0	2.7	2.5	112	5	130.6	2.4	1.8	132	
		<u>Specimen BG-5</u>									
All Method	7	155.6	1.4	0.9	156						
AVL OMNI	5	155.2	1.1	0.7	156						

Medical Laboratory Evaluation

25 Massachusetts Ave NW Ste 700

Washington, DC 20001-7401

800-338-2746 • 202-261-4500 • Fax: 202-835-0440

www.acponline.org/mle